PERIPHERAL MYELIN PROTEIN-22 EXPRESSION IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A SURAL NERVE BIOPSIES

被引:76
作者
HANEMANN, CO
STOLL, G
DURSO, D
FRICKE, W
MARTIN, JJ
VAN BROECKHOVEN, C
MANCARDI, GL
BARTKE, I
MULLER, HW
机构
[1] BOEHRINGER MANNHEIM GMBH, PENZBERG, GERMANY
[2] UNIV ANTWERP, BORN BUNGE FDN, NEUROPATHOL LAB, B-2020 ANTWERP, BELGIUM
[3] UNIV ANTWERP, BORN BUNGE FDN, NEUROGENET LAB, ANTWERP, BELGIUM
[4] UNIV GENOA, IST CLIN NEUROL, GENOA, ITALY
[5] IST SUPER SANITA, ROME, ITALY
关键词
HUMAN; CHARCOT-MARIE-TOOTH DISEASE; PERIPHERAL MYELIN PROTEIN; NORTHERN BLOT; IMMUNOHISTOCHEMISTRY;
D O I
10.1002/jnr.490370513
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Peripheral myelin protein-22 (PMP22) is expressed in myelinating Schwann cells and shows significant homology to murine growth arrest-specific gene gas3. Charcot-Marie-Tooth disease type 1a (CMT1a) is a common hereditary demyelinating neuropathy. Recently it was demonstrated that the gene for PMP22 is duplicated in CMT1a patients. A gene dosage mechanism has been postulated to cause CMT1a. According to this hypothesis, the increase in copy number of PMP22 gene would lead to an elevated expression of PMP22 and thereby cause the demyelinating phenotype of CMT1a. In the present communication we analyzed PMP22 mRNA and protein expression in sural nerve biopsies from CMT1a patients and normal controls. We show that PMP22 mRNA expression in CMT1a is not uniform. We found both elevated as well as normal PMP22 mRNA levels in patients. Interestingly, the highest PMP22 mRNA level was found in the least affected patient. In contrast to the mRNA levels, PMP22 was clearly reduced in all CMT1a patients as shown by immunohistochemistry. Thus the CMT1a phenotype may not be strictly correlated with increased PMP22 mRNA and protein expression. Possible roles of PMP22 in the pathogenesis of CMT1a are discussed. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:654 / 659
页数:6
相关论文
共 28 条
[1]   PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO THE MAJOR PERIPHERAL MYELIN GLYCOPROTEIN-PO [J].
BOLLENSEN, E ;
SCHEIDT, P ;
SCHACHNER, M .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (04) :1110-1114
[2]   TRISOMY-17P ASSOCIATED WITH CHARCOT-MARIE-TOOTH NEUROPATHY TYPE-1A PHENOTYPE - EVIDENCE FOR GENE DOSAGE AS A MECHANISM IN CMT1A [J].
CHANCE, PF ;
BIRD, TD ;
MATSUNAMI, N ;
LENSCH, MW ;
BROTHMAN, AR ;
FELDMAN, GM .
NEUROLOGY, 1992, 42 (12) :2295-2299
[3]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[4]   AN INTERSTITIAL DUPLICATION OF THE X-CHROMOSOME IN A MALE ALLOWS PHYSICAL FINE MAPPING OF PROBES FROM THE XQ13-Q22 REGION [J].
CREMERS, FPM ;
PFEIFFER, RA ;
VANDEPOL, TJR ;
HOFKER, MH ;
KRUSE, TA ;
WIERINGA, B ;
ROPERS, HH .
HUMAN GENETICS, 1987, 77 (01) :23-27
[5]   DIAGNOSTIC-CRITERIA FOR AUTOSOMAL-DOMINANT HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE-IA [J].
DEVISSER, M .
NEUROMUSCULAR DISORDERS, 1993, 3 (01) :77-79
[6]  
DYCK PJ, 1992, PERIPHERAL NEUROPATH, P1094
[7]  
HANEMANN CO, 1991, INT S SIGNAL TRANSFE
[8]   COEXPRESSION OF PMP22 GENE WITH MBP AND P(O) DURING DE-NOVO MYELINATION AND NERVE REPAIR [J].
KUHN, G ;
LIE, A ;
WILMS, S ;
MULLER, HW .
GLIA, 1993, 8 (04) :256-264
[9]   THE MOLECULAR-GENETICS OF MYELINATION - AN UPDATE [J].
LEMKE, G .
GLIA, 1993, 7 (04) :263-271
[10]   GENE DOSAGE IS A MECHANISM FOR CHARCOT-MARIE-TOOTH DISEASE TYPE-1A [J].
LUPSKI, JR ;
WISE, CA ;
KUWANO, A ;
PENTAO, L ;
PARKE, JT ;
GLAZE, DG ;
LEDBETTER, DH ;
GREENBERG, F ;
PATEL, PI .
NATURE GENETICS, 1992, 1 (01) :29-33